TICKERNERD
Menu
FBLGFBLGHealthcare · Biotechnology

FBLG Stock Forecast: FibroBiologics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.61
−6.94% on the day

The 2 Wall Street analysts covering FibroBiologics, Inc. hold a median 12-month price target of $13 — +676.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$10.7M
Ticker Nerd rank
46 / 100
Median analyst target
$13
Analysts covering
2
Revenue$0.0
Operating income−$4.0M
Net income−$4.1M
Free cash flow−$3.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.5%
1M
+56.3%
YTD
−64.2%
1Y
−85.8%
From 52W high
−86.8%
From 52W low
+156.8%
$1
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FBLG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores FibroBiologics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
46 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
92
Revisions
82
Accruals
76
Issuance
62
Volatility
50
Growth
46
Quality
14
Value
13
Momentum
4

Size (92): Smaller than most of the companies we track.

Momentum (4): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FBLG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FBLG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Oct 25Jan 26Apr 26Jul 26FBLGHigh $19Median $13Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
1 Buy1 Hold0 Sell
Low $6Median $13High $19

The green dot is the last close — the median target sits +676.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Aug 2026HC Wainwright & Co.MaintainsBuy$8.00 → $6.00
4 May 2026Maxim GroupDowngradeHold—
4 May 2026Maxim GroupDowngradeHold—
16 Apr 2026HC Wainwright & Co.MaintainsBuy—
26 Mar 2026D. Boral CapitalDowngradeHold—
12 Mar 2026D. Boral CapitalMaintainsBuy—
26 Feb 2026HC Wainwright & Co.MaintainsBuy—
25 Feb 2026D. Boral CapitalMaintainsBuy—
6 Jan 2026D. Boral CapitalMaintainsBuy—
2 Jan 2026HC Wainwright & Co.ReiteratesBuy—
20 Nov 2025D. Boral CapitalMaintainsBuy—
5 Nov 2025HC Wainwright & Co.MaintainsBuy—
3 Nov 2025D. Boral CapitalMaintainsBuy—
12 Sept 2025HC Wainwright & Co.ReiteratesBuy—
10 Sept 2025D. Boral CapitalMaintainsBuy—
5 Aug 2025HC Wainwright & Co.MaintainsBuy—
4 Aug 2025D. Boral CapitalMaintainsBuy—
29 July 2025D. Boral CapitalMaintainsBuy—
9 July 2025D. Boral CapitalMaintainsBuy—
17 June 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FBLG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

FBLG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, FibroBiologics, Inc. returned −85.8% against +17.5% for the S&P 500, dividends included.

FBLG vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26FBLGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FBLG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

FibroBiologics, Inc. (FBLG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 78% of US stocks

Price / sales
—
Price / book
2.1×

Cheaper than 44% of US stocks

EV / EBITDA
−0.5×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−660.1%

Higher than 2% of US stocks

Return on assets
−95.8%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

FibroBiologics, Inc. (FBLG) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • FibroBiologics, Inc. has a market value of $10.7M and an enterprise value of $8.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$18.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$14.8M.

  • Shares outstanding: 6.1M.

  • Trailing P/E: −0.2×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • FibroBiologics, Inc. employs 15 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

FBLG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FBLGFibroBiologics, Inc.$10.7M
46
LNAILunai Bioworks, Inc.$10.8M
33
AZTRAzitra, Inc.$10.8M
21
KALAKala Bio, Inc.$10.6M
15
VTGNVistaGen Therapeutics, Inc.$10.5M
29
MTVAMetaVia, Inc.$10.9M
17
INABIN8bio, Inc.$10.4M
42

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own FibroBiologics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FBLG news & analysis

FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing

PRNewsWire · 3 Sept 2026positive

FibroBiologics announced that the USPTO has issued a new U.S. patent covering the topical administration of 3D spheroid fibroblasts and fibroblast-derived materials for treating and accelerating wound healing.

Why it matters — This expands FibroBiologics' patent portfolio in wound-healing therapeutics, reinforcing its intellectual property position in fibroblast-based treatments.

FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media

PRNewsWire · 1 Sept 2026positive

FibroBiologics announced that the United States Patent and Trademark Office has issued a new U.S. patent covering methods of promoting disc regeneration using components derived from stimulated fibroblasts, for the treatment of degenerative disc disease.

Why it matters — The new patent expands FibroBiologics' intellectual property portfolio, which now includes 270+ issued and pending patents, potentially strengthening its position in fibroblast-based therapeutics for chronic diseases.

FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia

Proactive Investors · 27 Aug 2026positive

FibroBiologics released and shipped the third batch of its experimental drug product, CYWC628, to Australia to support its ongoing clinical trial for diabetic foot ulcers (DFUs). The investigational treatment is a topically applied allogeneic cell therapy that uses donor fibroblasts to accelerate wound healing.

Why it matters — This shipment signals continued progress in advancing FibroBiologics' key clinical program for diabetic foot ulcers.

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

PRNewsWire · 27 Aug 2026positive

FibroBiologics announced the release of the third batch of its CYWC628 drug product, which has passed required safety and quality testing under cGMP standards and has been shipped to Australia to support the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers.

Why it matters — This marks continued progress in the company's CYWC628 clinical supply chain for its diabetic foot ulcer trial, signaling advancement of a key pipeline program.

FibroBiologics Regains Compliance with Nasdaq Trading Rules

PRNewsWire · 26 Aug 2026positive

FibroBiologics received confirmation from Nasdaq on August 25, 2026 that it has regained compliance with the bid price requirement in Listing Rule 5550(a)(2). The company is now in compliance with all Nasdaq listing standards and its common shares will continue trading on the Nasdaq Capital Market under the ticker "FBLG."

Why it matters — This confirms FibroBiologics has resolved a potential delisting risk, ensuring its shares remain listed and tradable on the Nasdaq Capital Market.

FAQ

Frequently asked questions about FBLG stock

What is the FBLG stock price forecast for 2026-2027?

The 2 Wall Street analysts covering FibroBiologics, Inc. have a median 12-month price target of $13, with estimates ranging from $6 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FBLG stock a buy right now?

Of the 2 analysts covering FibroBiologics, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks FibroBiologics, Inc. 46 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FBLG?

As at 12 Sept 2026, FibroBiologics, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

Will FBLG stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +676.4% from the last close, and Ticker Nerd's factor model ranks FibroBiologics, Inc. 46 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FBLG stock forecast for 2030?

No analyst covering FibroBiologics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FBLG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $19 over the next 12 months.

How has FBLG stock performed over the past year?

FibroBiologics, Inc. returned -85.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does FibroBiologics, Inc. do?

FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing fibroblast-based therapies for chronic diseases.

What is the latest news on FBLG?

The most recent item we track (PRNewsWire, 3 Sept 2026): "FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing". FibroBiologics announced that the USPTO has issued a new U.S. patent covering the topical administration of 3D spheroid fibroblasts and fibroblast-derived materials for treating and accelerating wound healing.

Company

About FibroBiologics, Inc.

FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing fibroblast-based therapies for chronic diseases. Its current programs center on regenerative medicine and cell therapy applications for conditions such as wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and certain cancers. The company’s pipeline includes product candidates such as CYWC628, CYMS101, CYPS317, and CybroCell, which are being developed to address areas of significant unmet medical need. FibroBiologics also works with fibroblast cells and fibroblast-derived materials in research programs related to tissue regeneration and immune modulation. Based in Houston, Texas, FibroBiologics plays a specialized role in the biotechnology market by advancing cell-based approaches designed for therapeutic use across several disease areas.

CEO Mr. Peter O'Heeron · 15 employees · United States · https://fibrobiologics.com